Daliresp

Roflumilast (Daliresp®, Daxas®) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary… (More)

Roflumilast therapy has a limited role in patients with severe COPD, and no role in patients with mild to moderate COPD. It will… (More)

Objective To identify the structure of the new drug daliresp. Methods The structure of daliresp w as identified by UV,IR,MS,1H… (More)

APIXABAN (ELIQUIS®) FOR ORAL ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION hronic obstructive pulmonary disease (COPD) is a… (More)

PURPOSE The pharmacology, pharmacokinetics, efficacy, and safety of roflumilast-the first in a new class of agents for managing… (More)

Chronic obstructive pulmonary disease (COPD) is characterized by a gradual and progressive loss of lung function. The consensus… (More)

is substantial. Quality of life, morbidity, and mortality are all negatively affected by the disease. In the National Health and… (More)

 

Roflumilast (Daxas® [EU], Daliresp® [USA]) is the first phosphodiesterase 4 inhibitor approved in Europe to be used in severe… (More)

roflumilast Chronic obstructive pulmonary disease (COPD) is a progressive, irreversible lung disease that is often associated… (More)